ReVance Therapeutics, Inc. Announces Clinical Trial Results of RT001 Topical Gel Presented at the Annual Meeting of the American Society for Dermatologic Surgery

Published: Oct 25, 2010

NEWARK, Calif.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (“Revance”) today announced that the results of two Phase 2b clinical trials on RT001, a topical botulinum toxin type A which is under investigation for the treatment of lateral canthal lines (crow’s feet wrinkles) were presented at the annual meeting of the American Society of Dermatologic Surgery in Chicago. Both multi-center, double-blind, randomized, controlled studies showed that RT001 was well tolerated and demonstrated statistically significant efficacy versus controls. Adverse events were unrelated to study treatment as rated by the investigators and generally mild or moderate, and transient. There was no evidence of spread or diffusion away from the target muscle observed.

Back to news